Medical Information Search Coronavirus (COVID-19) and the Use of CIMZIA® (certolizumab pegol) Read important information related to your request The material below is provided in response to your specific search for information on UCBCOMPASS® IMMUNOLOGY and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. See FDA-approved indications . CIMZIA® is associated with a BOXED WARNING regarding serious infections and malignancy and important WARNINGS AND PRECAUTIONS, including heart failure, anaphylaxis or serious allergic reactions, hepatitis B virus reactivation, demyelinating disease, cytopenias or pancytopenia, and Lupus-like syndrome. Please review the Full Prescribing Information here. This material is not for distribution or reproduction. FDA-Approved Indications CIMZIA® is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy Treatment of adults with moderately to severely active rheumatoid arthritis Treatment of adult patients with active psoriatic arthritis Treatment of adults with active ankylosing spondylitis Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy Download VIEW PDF Thumbnails Document Outline Attachments Previous Next Highlight all Match case Whole words Presentation Mode Open Print Download Current View Go to First Page Go to Last Page Rotate Clockwise Rotate Counterclockwise Text Selection Tool Hand Tool Vertical Scrolling Horizontal Scrolling Wrapped Scrolling No Spreads Odd Spreads Even Spreads Document Properties… Toggle Sidebar Find Previous Next Presentation Mode Open Print Download Current View Tools Zoom Out Zoom In Automatic Zoom Actual Size Page Fit Page Width 50% 75% 100% 125% 150% 200% 300% 400% CLOSE PDF More Information Less Information Close Enter the password to open this PDF file: Cancel OK File name: - File size: - Title: - Author: - Subject: - Keywords: - Creation Date: - Modification Date: - Creator: - PDF Producer: - PDF Version: - Page Count: - Page Size: - Fast Web View: - Close Preparing document for printing… 0% Cancel Was this content helpful? 1000 characters remaining To report a suspected adverse event or productquality complaint, please complete our online webform. Your may also contact ucbCARES® at1-844-599-CARE (2273) or email ucbcares@ucb.com Send Feedback To report a suspected adverse event or productquality complaint, please complete our online webform. Your may also contact ucbCARES® at1-844-599-CARE (2273) or email ucbcares@ucb.com Prescribing Information CIMZIA® (certolizumab pegol) Prescribing Information